Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib in HER2‐Mutant Lung Adenocarcinoma

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)‐mutant lung cancer remains an orphan of specific targeted therapy. The variable responses to anti‐HER2 therapies in these patients prompt us to examine impact of HER2 variants and co‐mutations on responses to anti‐HER2 treatments in lung ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Fang, Wenfeng, Zhao, Shen, Liang, Ying, Yang, Yunpeng, Yang, Lin, Dong, Xiaorong, Zhang, Li, Tang, Yong, Wang, Shoufeng, Yang, Yang, Ma, Xiaoyan, Wang, Minghui, Wang, Wenjing, Zhao, Songhui, Wang, Kai, Gao, Song
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066719/
https://ncbi.nlm.nih.gov/pubmed/32162827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0547
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados